Pricing Log in Create free account

MapLight Therapeutics, Inc. (MPLT) vs Prothena Corporation plc (PRTA)

MapLight Therapeutics, Inc. and Prothena Corporation plc are both Biotechnology companies. MapLight Therapeutics, Inc. and Prothena Corporation plc are of similar size ($445.7M and $436.4M). MapLight Therapeutics, Inc. has the higher net margin (0.00% vs −80.7%) and the lower return on invested capital (−348.4% vs 0.00%). Across the 12 metrics below, Prothena Corporation plc leads on 7 and MapLight Therapeutics, Inc. on 5.

Valuation

Metric MPLT PRTA Biotechnology median
P/E n/m n/m 8.50
P/S n/m 7.98 9.71
P/B 1.00 1.52 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 2.70 9.21
Earnings yield (549.48%) (9.94%) (33.15%)
Free cash flow yield (50.06%) (13.96%) (25.50%)

Profitability

Metric MPLT PRTA Biotechnology median
Gross margin — 100.00% 65.16%
Operating margin 0.00% (101.80%) 0.00%
Net margin 0.00% (80.67%) 0.00%
Free cash flow margin 0.00% (111.49%) 0.00%
Return on equity (297.18%) (14.39%) (56.36%)
Return on assets (124.79%) (12.54%) (48.04%)
Return on invested capital (348.44%) 0.00% 0.00%

Growth

Metric MPLT PRTA Biotechnology median
Revenue growth (TTM) — 427.32% 6.02%
EPS growth (last fiscal year) 82.39% (99.56%) 30.26%
Revenue growth, 5-year CAGR — 62.56% 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric MPLT PRTA Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 16.52 25.05 4.72
Net debt to EBITDA 1.79 1.46 0.96

Dividend

Metric MPLT PRTA Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric MPLT PRTA Biotechnology median
Market cap 445.72m 436.36m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack